Plasmid vector and method for simultaneously displaying two polypeptides or proteins on MS2-VLP surface

By simultaneously displaying polypeptides and proteins on the surface of MS2 VLP, the problem of restriction of single type display in the prior art is solved, and the stable display of polypeptides and proteins is achieved, which enhances its potential in vaccines and detection applications.

CN119082159APending Publication Date: 2024-12-06GUANGZHOU MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411225978.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-03
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

In the prior art, the MS2 VLP surface can only display one type of polypeptide or protein, which limits its application in biological detection and vaccine preparation, and the selectivity of exogenous polypeptide or protein insertion sites is low, resulting in instability problems. .

Method used

By fusing polypeptide 1 and carboxy-terminal exogenous protein 2 in the middle of the single-chain dimer of the CP protein, a plasmid vector is designed to display polypeptide 1 and protein 2 at the same time, and a linker sequence is added between the coding sequences of the amber codon TAG and polypeptide 2. , increase purification tags and promoters to improve expression potency and stability.

Benefits of technology

The MS2 VLP surface simultaneously displays two different types of peptides or proteins, which improves its application potential in vaccine preparation and biological detection, and enhances the transformation and expression stability of plasmid vectors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082159A_ABST
    Figure CN119082159A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, and particularly relates to the technical field of display of protein or polypeptide on the surface of bacteriophage. The invention provides a method for displaying two different types of polypeptides or proteins on the surface of MS2 VLP. The method mainly comprises two steps of plasmid vector construction and expression. The constructed plasmid vector at least contains a packaging sequence, an MS2 bacteriophage single-chain dimer CP gene sequence and coding sequences of a polypeptide 1 and a polypeptide 2 which need to be displayed; the coding sequence of the polypeptide 1 is located in the middle of the CP protein single-chain dimer, the coding sequences of the amber codon TAG and the polypeptide 2 are located at the carboxyl end of the CP protein single-chain dimer, and the CP gene at least comprises a sequence for coding the protein as shown in SEQ ID NO.2. The plasmid vector is transferred into a competent cell to obtain the MS2-VLP of which the surface simultaneously displays two polypeptides or proteins. The technology has wide application in the aspects of biological detection and vaccine preparation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and in particular relates to the technical field of displaying proteins or polypeptides on the surface of bacteriophages. Background Art

[0002] MS2 VLP (MS2 Virus Like Particle) is an artificial virus-like particle based on the transformation of MS2 bacteriophage (host is Escherichia coli). MS VLP has simple components and clear formation mechanism. In short, it includes three components: CP protein, mature protein A and RNA carrying pac sequence (pac RNA). Among them, the 2-mer formed by 2 CP molecules interacts with the pac RNA sequence to trigger spontaneous assembly, and finally 90 CP 2-mers and 1 molecule of A protein form virus-like particles that encapsulate exogenous RNA. MS2-VLP has good stability and its particle cavity can also encapsulate exogenous RNA. Therefore, it has been widely studied and applied in nucleic acid standards, drug delivery, subunit vaccines, etc. However, the surface of the above-mentioned MS2 VLP only displays one type of polypeptide or protein, which limits the application of MS2 VLP in biological detection and vaccine preparation.

[0003] Since CP protein or single-chain dimer CP protein can be used for the preparation of MS2 VLP, there are many options for the sites of exogenous peptides or proteins displayed in MS2 VLP, including the N or C terminus of CP protein, and the N, C or middle position of single-chain dimer CP protein. Robert A et al. confirmed that random peptides up to 24 amino acids can be inserted into the AB loop at the N-terminus of MS2 CP protein, but it often destroys the ability of the coat protein to fold correctly, leading to instability caused by aggregation or proteolytic degradation. David S. Peabody et al. (1997) fused the two subunits of MS2 CP protein dimer to form a single-chain dimer of CP protein, which improved the tolerance of VLP to the insertion of exogenous peptides. Lukai Zhai et al. (2017) inserted different HPV L2 epitopes into the N terminus of MS2 CP protein single-chain dimer and successfully constructed vaccines for multiple HPV types. P. Mikel et al. fused the peptide His Tag tag in the middle of the CP protein single-chain dimer to optimize the purification of MS2 VLP. In the prior art, proteins displayed on the surface of MS2 VLP are all one type of polypeptide or protein. Summary of the invention

[0004] In view of the shortcomings of the prior art, the purpose of the present invention is to break through the limitation of the prior art that only one type of polypeptide or protein is displayed on the surface of MS2 VLP, and to realize the simultaneous display of two different polypeptides or proteins, polypeptide 1 and protein 2, on the surface of MS2 VLP. The present invention fuses polypeptide 1 in the middle of the CP protein single-chain dimer and fuses exogenous protein 2 at the carboxyl end, so as to realize the simultaneous display of two different polypeptides or proteins, polypeptide 1 and protein 2, on the surface of MS2 VLP.

[0005] The present invention provides a plasmid vector, which is characterized in that: the plasmid vector at least contains a packaging sequence as shown in SEQ ID NO.1, an MS2 phage single-chain dimer CP gene sequence and coding sequences of polypeptides 1 and 2 to be displayed; the coding sequence of polypeptide 1 is located in the middle of the CP protein single-chain dimer, an amber codon TAG and the coding sequence of polypeptide 2 are located at the carboxyl end of the CP protein single-chain dimer, and the CP gene at least contains a sequence encoding a protein as shown in SEQ ID NO.2.

[0006] Specifically, in order to facilitate the purification of proteins expressed in the plasmid vector, the carboxyl terminus of the polypeptide 2 coding sequence in the above plasmid vector is fused with a purification tag polyhistidine, the sequence of which is shown in SEQ ID NO.3.

[0007] Specifically, in order to improve the efficiency of the plasmid in displaying polypeptide 2, a linker sequence is added between the amber codon TAG and the coding sequence of polypeptide 2 of the above-mentioned plasmid vector, and the amino acids encoded by the linker sequence include proline and glycine.

[0008] Preferably, in order to improve the yield of MS2 phage display expressed after plasmid transformation, the plasmid vector has a promoter at the 5' end of the coding sequence of the MS2 phage single-chain dimer CP gene and the polypeptide 1 and polypeptide 2 to be displayed.

[0009] Preferably, the above promoter is an arabinose promoter, and its sequence is shown in SEQ ID NO.4.

[0010] Preferably, in order to improve the stability of MS2 phage expressed after the plasmid vector is transformed, a protein A encoding sequence as shown in SEQ ID NO.6 is added to the plasmid vector.

[0011] Specifically, the sequence of the plasmid vector is shown as SEQ ID NO.7.

[0012] The method for displaying two different types of polypeptides or proteins on the surface of MS2 VLP provided by the present invention comprises the following steps:

[0013] (1) constructing a plasmid vector;

[0014] (2) The plasmid vector constructed in step (1) is transferred into competent cells for expression to obtain MS2 VLPs displaying polypeptide 1 and polypeptide 2 on the surface.

[0015] Furthermore, the present invention provides a method for displaying two different types of polypeptides or proteins on the surface of MS2 VLP, wherein the competent cell is an amber mutant Escherichia coli E. coli XL1blue.

[0016] Furthermore, the invention provides a method for displaying two different types of polypeptides or proteins on the surface of MS2 VLP, wherein the polypeptide 1 coding sequence contains the SpcT coding sequence as shown in SEQ ID NO.5, and further comprises the following steps:

[0017] (3) Design and synthesize the N16-SpyC fusion protein coding sequence, as shown in SEQ ID NO.8, and clone the N16-SpyC fusion protein coding sequence into the pET11a vector through the two restriction sites of NdeI and BamHI to obtain the expression vector pET-N16-SpyC.

[0018] (4) pET-N16-SpyC was transferred into competent cells, induced with IPTG, and purified by nickel column to obtain N16-SpyC protein;

[0019] (5) Incubate N16-SpyC with the MS2 VLP obtained in step (2), and display N16-SpyC on the surface of MS2 VLP via SpyT.

[0020] Beneficial Effects

[0021] The present invention simultaneously displays two proteins or polypeptides on the surface of MS2 VLP. This technology can be applied to prepare multi-epitope vaccines against the same pathogen or tumor, or to prepare multi-unit vaccines by expressing epitopes of different pathogens or tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 It is a schematic diagram of the structure of the single-chain dimer CP gene and the coding sequences of polypeptide 1 and polypeptide 2. DETAILED DESCRIPTION

[0023] In order to enable ordinary technicians in this research field to better understand the present invention, the present invention is further described below in conjunction with specific embodiments and drawings. The specific embodiments are not used to limit the present invention.

[0024] The reagents and consumables information used in the specific embodiments are shown in the following table:

[0025]

[0026] Instruments used in specific embodiments

[0027] Clean bench, water bath, constant temperature incubator, constant temperature shaker, protein purifier, low temperature high speed centrifuge, developer.

[0028] Identification methods used in specific embodiments

[0029] The detection and identification methods adopted by the present invention are conventional experimental methods: SDS-PAGE, WB, and agarose gel electrophoresis.

[0030] Embodiment 1

[0031] In this example, two different polypeptides and proteins are simultaneously displayed on the surface of MS2 VLP in vivo. Peptide 1 contains SpyT (its sequence is shown in SEQ ID NO.5), and polypeptide 2 is polyhistidine (its sequence is shown in SEQ ID NO.3).

[0032] The method for simultaneously displaying two different peptides and proteins on the surface of MS2-VLP is as follows: 1. Construct a vector

[0033] The sequence commissioned to be synthesized is shown in SEQ ID NO.9, and is constructed into the pBADhisA vector through NcoI and HindIII to obtain the pBAD-2MS2 vector, whose sequence is shown in SEQ ID NO.7. The pBADhisA vector carries the arabinose promoter. The pBAD-2MS2 vector contains the arabinose promoter, whose sequence is shown in SEQ ID NO.4, the packaging sequence (whose sequence is shown in SEQID NO.1), the single-chain dimer CP protein (whose sequence is shown in SEQ ID NO.2), polypeptide 1 contains the SpyT polypeptide, polypeptide 2 contains polyhistidine, and there is a linker sequence between polypeptide 2 and the amber codon. The structural schematic diagram of the single-chain dimer CP gene in SEQ ID NO.9 and the polypeptide 1 and polypeptide 2 coding sequences is shown in Figure 1 shown.

[0034] The sequence information shown in SEQ ID NO.9 is as follows:

[0035] (1) Positions 51-392 and 504-845 encode CP protein (the sequence of which is shown in SEQ ID NO.2);

[0036] (2) Positions 393-503 encode polypeptide 1, wherein positions 447-495 encode SpcT, the sequence of which is shown in SEQ ID NO.5;

[0037] (3) Positions 846-848 are the amber codon TAG;

[0038] (4) Positions 849-881 encode linker, positions 882-899 encode polyhistidine, the sequence is shown in SEQ ID NO.3;

[0039] (5) Positions 923-941 are the packaging sequence, as shown in SEQ ID NO.1.

[0040] (6) Positions 1052-2281 encode protein A and related sequences, positions 1101-2281 encode protein A, and the sequence is shown in SEQ ID NO.6.

[0041] 2. pBAD-2MS2 vector was transferred into amber mutant strain for expression

[0042] (1) Escherichia coli XL-1-BLUE amber mutant strain was used as the expression host of pBAD-2MS2;

[0043] (2) Purchase competent cells XL-1-BLUE from Weidi Company, and transfer pBAD-2MS2 into XL-1-BLUE according to the instructions, and pick positive colonies for expression;

[0044] (3) Activate the positive colonies overnight, take the overnight bacterial solution and add it to fresh medium containing antibiotics at a ratio of 1:100 for 3 hours, then add arabinose for induction. After 12 hours, recover the bacteria;

[0045] (4) The cells were resuspended in PBS and disrupted by ultrasound. The disrupted liquid was centrifuged at 12,000 g for 10 min, and the supernatant was taken. RNase and DNase were added and digested at 37°C for 30 min. 10 μl of the supernatant was subjected to DNA agarose electrophoresis to identify whether MS2 VLPs were formed.

[0046] 3. Purification of MS2 VLPs

[0047] (1) purifying the supernatant containing MS2 VLPs by nickel column affinity chromatography;

[0048] (2) The purification instrument was an AKTA avant chromatograph (protein purification system). The purification process was carried out according to the operating instructions, and finally 250 mM imidazole was used to elute to obtain MS2 VLPs;

[0049] (3) Identification of MS2 VLPs by SDS-PAGE and Western Blot (WB)

[0050] 4. Result detection:

[0051] (1) The pBAD-2MS2 vector was transferred into E. coli XL-1-BLUE and induced to express by arabinose. The information of each lane in the DNA agarose electrophoresis identification of MS2 VLP results (not shown) is as follows: 1: broken supernatant without adding DNase and RNase; 2: broken supernatant after adding DNase and RNase digestion; 3: affinity chromatography purification sample after adding DNase and RNase digestion; M: 250-10000bp DNA Marker. From the results shown in the DNA agarose electrophoresis identification of MS2 VLP results, it can be seen that after the supernatant after expression is digested with RNase and DNase, there is a clear band at 2000bp. This shows that pBAD-2MS2 can form MS2 VLP in XL-1-BLUE.

[0052] (2) The supernatant containing MS2 VLP was purified by nickel column affinity chromatography, and the purified sample was obtained after elution with 250mM imidazole, and then subjected to SDS-PAGE and WB identification. The identification results are shown in the protein electrophoresis result diagram of purified MS2-VLP (not shown in the figure). The information of each lane in the protein electrophoresis result diagram of purified MS2-VLP is as follows: M: protein marker; 1: sample before induction with 20% arabinose; 2: sample after induction with 20% arabinose; 3: supernatant sample after crushing; 4: 250mM imidazole elution peak sample. The results showed that the sample purified in lane 3 contained MS2 VLP, and the purified sample (lane 4) had a clear band near 25-33 kDa. The incubation antibody was anti-His-HRP mouse antibody, and the results were shown in the WB result diagram of purified MS2-VLP (not shown). The information of each lane in the figure is as follows: M: protein marker; 1: sample before induction with 20% arabinose; 2: sample after induction with 20% arabinose; 3: supernatant sample after disruption; 4: 250 mM imidazole elution peak sample. The results showed that the band (lane 4) carried the His tag, which was consistent with expectations, indicating that the purified MS2 VLP displayed a polyhistidine tag.

[0053] 5. Reaction of MS2 VLP with N16-SpyC to display NBPD-1 on the surface of MS2 VLP

[0054] In order to verify that the SpyT displayed by the above MS2 VLP can display foreign proteins on the surface of MS2 VLP through SpyC, SpyC was fused with the nanoantibody N16 and expressed, and then incubated with MS2 VLP for identification.

[0055] (1) Expression and purification of N16-SpyC. The coding sequence of N16-SpyC fusion protein was designed and synthesized, as shown in SEQ ID NO.8. SEQ ID NO.8 was synthesized by Bio-Industry and cloned into pET11a vector through two restriction sites, NdeI and BamHI, to obtain the expression vector pET-N16-SpyC.

[0056] The sequence information of SEQ ID NO.8 is: positions 4-378 encode N16 nanobody, positions 409-747 encode SpyC, positions 784-807 encode polyhistidine, and the rest of the sequence is a random sequence encoding amino acids;

[0057] (2) pET-N16-SpyC was transferred into bl21(DE3) competent cells, induced by IPTG, and purified by nickel column to obtain N16-SpyC protein;

[0058] (3) After incubating the N16-SpyC protein with the above-mentioned MS2 VLP at 37 degrees for 1 hour, SDS-PAGE was used to identify whether N16-SpyC was bound to MS2 VLP.

[0059] Test results

[0060] The results after N16-SpyC expression and purification are shown in the SDS-PAGE purification effect diagram of PD-1 (not shown), and the information of each lane in the figure is: M: protein marker; 1: bacterial protein before induction; 2: bacterial protein after 1mM IPTG induction; 3: soluble supernatant sample after induction; 4: precipitate sample after induction; 5: discarded liquid sample during nickel column purification; 6, 7, 8: purified samples after elution with 250mM imidazole. The results show that after IPTG induction, the sample has obvious bands near 30-35kDa, and a relatively pure sample is obtained near this position after nickel column purification. This shows that N16-SpyC was successfully expressed and purified;

[0061] N16-SpyC was incubated with MS2 VLP, and the binding of N16-SpyC to MS2 VLP was identified by SDS-PAGE. The results are shown in the SDS-PAGE identification result diagram of the reaction of N16-SpyC nanobody with MS2-VLP (not shown), and the information of each lane in the figure is: M: protein marker; 1: MS2-VLP sample; 2: N16-SpyC sample; 3: N16-SpyC sample and MS2-VLP sample were mixed and connected at a molar ratio of 4:1 and then loaded; 4: N16-SpyC sample and MS2-VLP sample were mixed and connected at a molar ratio of 2:1 and then loaded; 5: N16-SpyC sample and MS2-VLP sample were mixed and connected at a molar ratio of 1:1 and then loaded; 6: N16-SpyC sample and MS2-VLP sample were mixed and connected at a molar ratio of 1:2 and then loaded. The results shown in the figure show that after N16-SpyC and MS2 VLP were co-incubated at different ratios, a clear band appeared near 60-70 kDa, which was consistent with expectations. This shows that N16-SpyC can be displayed on the surface of MS2 VLP through SpyT.

[0062] Background technology of the present invention relates to literature

[0063] [1]Fu Y, Li JA novel delivery platform based on Bacteriophage MS2virus-like particles. Virus Res. 2016; 211:9-16.

[0064] [2] Hashemi K, Ghahramani Seno MM, Ahmadian MR, Malaekeh-Nikouei B, Bassami MR, Dehghani H, Afkhami-Goli A. Optimizing the synthesis and purification of MS2 virus like particles. Sci Rep. 2021 Oct 6; 11(1): 19851.

[0065] [3] Muyldermans S. Nanobodies: natural single-domain antibodies. AnnuRevBiochem.2013;82:775-97.

[0066] [4]Weiss RA,Verrips CT.Nanobodies that Neutralize HIV.Vaccines(Basel).2019Jul 31;7(3):77.

[0067] [5]de Marco A.Recombinant expression of nanobodies and nanobody-derived immunoreagents.Protein Expr Purif.2020Aug;172:105645.

[0068] [6]Zakeri B,Fierer JO,Celik E,Chittock EC,Schwarz-Linek U,Moy VT,Howarth M.Peptide tag forming a rapid covalent bond to a protein,throughengineering abacterial adhesin.Proc Natl Acad Sci U S A.2012Mar 20;109(12):E690-7.

[0069] [7]Tian J,Jia R,Wenge D,Sun H,Wang Y,Chang Y,Luo H.One-steppurification and immobilization of recombinant proteins using SpyTag / SpyCatcher chemistry.Biotechnol Lett.2021May;43(5):1075-1087.

[0070] [8]Wang W,Liu Z,Zhou X,Guo Z,Zhang J,Zhu P,Yao S,Zhu M.Ferritinnanoparticle-based SpyTag / SpyCatcher-enabled click vaccine for tumor immunotherapy.Nanomedicine.2019Feb;16:69-78.

Claims

1. A plasmid vector, characterized in that: The plasmid vector contains at least a packaging sequence as shown in SEQ ID NO.1, a MS2 phage single-chain dimer CP gene sequence and coding sequences of polypeptides 1 and 2 to be displayed; the coding sequence of polypeptide 1 is located in the middle of the CP protein single-chain dimer, the amber codon TAG and the coding sequence of polypeptide 2 are located at the carboxyl end of the CP protein single-chain dimer, and the CP gene contains at least a sequence encoding a protein as shown in SEQ ID NO.

2.

2. The plasmid vector according to claim 1, characterized in that: The carboxyl end of the coding sequence of the polypeptide 2 is fused with a purification tag polyhistidine, and the polyhistidine sequence is shown in SEQ ID NO.

3.

3. The plasmid vector according to claim 1, characterized in that: A linker sequence is added between the amber codon TAG and the coding sequence of polypeptide 2, and the amino acids encoded by the linker sequence contain proline and glycine.

4. The plasmid vector according to claim 1, characterized in that: The 5' ends of the coding sequences of the MS2 phage single-chain dimer CP gene and the polypeptide 1 and polypeptide 2 to be displayed have a promoter.

5. The plasmid vector according to claim 4, characterized in that: The promoter is an arabinose promoter, and its sequence is shown in SEQ ID NO.

4.

6. The plasmid vector according to claim 1, characterized in that: The plasmid vector also contains a sequence related to protein A coding, and the sequence related to protein A coding is shown in SEQ ID NO.

6.

7. The plasmid vector according to claim 1, characterized in that: The sequence of the plasmid vector is shown in SEQ ID NO.

7.

8. A method for displaying two different types of polypeptides or proteins on the surface of MS2 VLP, characterized in that: The following steps are involved: (1) constructing a plasmid vector as described in any one of claims 1 to 8; (2) The plasmid vector constructed in step (1) is transferred into competent cells for expression to obtain MS2 VLPs displaying polypeptide 1 and polypeptide 2 on the surface.

9. The method for displaying two different types of polypeptides or proteins on the surface of MS2 VLP according to claim 8, characterized in that: The competent cells in step (1) are amber mutant Escherichia coli.

10. The method for displaying two different types of polypeptides or proteins on the surface of MS2 VLP according to claim 8, characterized in that: The polypeptide 1 coding sequence contains the SpcT coding sequence as shown in SEQ ID NO.5, and further comprises the following steps: (3) Design and synthesize the N16-SpyC fusion protein coding sequence, as shown in SEQ ID NO.8, and clone the N16-SpyC fusion protein coding sequence into the pET11a vector through the two restriction sites of NdeI and BamHI to obtain the expression vector pET-N16-SpyC. (4) pET-N16-SpyC was transferred into competent cells, induced with IPTG, and purified by nickel column to obtain N16-SpyC protein; (5) Incubate N16-SpyC with the MS2 VLP obtained in step (2), and display N16-SpyC on the surface of MS2 VLP via SpyT.